What's Happening?
Anixa Biosciences has announced that Dr. Jose Conejo-Garcia, a co-inventor of Anixa's CAR-T technology, will be the keynote speaker at the South Carolina Clinical & Translational Research Institute 2026 Retreat. The event will focus on cell-based therapies
and will feature discussions on Anixa's ongoing Phase 1 clinical trial of liraltagene autoleucel (lira-cel), a CAR-T therapy for recurrent ovarian cancer. Anixa is collaborating with Moffitt Cancer Center on this novel therapy, which targets the follicle-stimulating hormone receptor (FSHR) on tumor cells.
Why It's Important?
The keynote by Dr. Conejo-Garcia highlights Anixa's advancements in CAR-T therapy, a promising area in cancer treatment. The focus on lira-cel, which targets specific receptors on cancer cells, represents a significant step in developing more effective and targeted cancer therapies. Anixa's collaboration with renowned institutions like Moffitt Cancer Center and Cleveland Clinic underscores its commitment to innovation and its potential to impact the oncology field significantly. The company's approach to partnering with leading research institutions allows it to leverage cutting-edge technologies and accelerate the development of new treatments.
What's Next?
Anixa will continue its Phase 1 trial of lira-cel, aiming to demonstrate its efficacy and safety in treating recurrent ovarian cancer. The company is also exploring additional cancer vaccines in collaboration with Cleveland Clinic, targeting various malignancies. Anixa's strategy of partnering with world-renowned research institutions will likely lead to further advancements in cancer immunotherapy. The outcomes of these trials and collaborations could pave the way for new treatment options and potentially improve patient outcomes in oncology.
